A single-dose study to investigate the effects of 4 different doses of inhaled AZD8683 in COPD patients
- Registry ID
- EUCTR2012-002900-42
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- AstraZeneca AB
- Start date
- 2012-08-27
- Last update
- 2026-08-16
Conditions
- Chronic obstructive pulmonary disease, COPD
Summary
To investigate the bronchodilatory effects of 4 different single doses of inhaled AZD8683 compared with placebo, with respect to peak and trough forced expiratory volume in the first second (FEV1), in patients with COPD.
Locations
View on source registry